ALXO
Alx Oncology Holdings
NASDAQ: ALXO · HEALTHCARE · BIOTECHNOLOGY
$1.70
+7.59% today
Updated 2026-04-30
Market cap
$212.60M
P/E ratio
—
P/S ratio
5,085.96x
EPS (TTM)
$-1.90
Dividend yield
—
52W range
$0 – $3
Volume
1.0M
Alx Oncology Holdings (ALXO) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.07M | $4.80M | $1.18M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | +132.0% | -75.4% | -100.0% | — | — | — | — |
| Cost of revenue | $1.88M | $4.36M | $1.07M | $736000.00 | $1.47M | $836000.00 | $872000.00 | — |
| Gross profit | $187000.00 | $436000.00 | $107000.00 | $-736000.00 | $-1.47M | $-836000.00 | $-872000.00 | — |
| Gross margin | 9.0% | 9.1% | 9.1% | — | — | — | — | — |
| R&D | $11.27M | $16.31M | $28.96M | $60.17M | $98.40M | $141.79M | $116.37M | $77.00M |
| SG&A | $2.60M | $3.31M | $14.81M | $23.39M | $29.04M | $28.48M | $26.09M | $23.85M |
| Operating income | $-13.68M | $-19.18M | $-43.66M | $-83.56M | $-127.44M | $-170.28M | $-142.47M | $-100.85M |
| Operating margin | -662.0% | -400.0% | -3694.0% | — | — | — | — | — |
| EBITDA | $-13.26M | $-18.76M | $-43.46M | $-83.42M | $-127.09M | $-158.40M | $-132.25M | $-100.85M |
| EBITDA margin | -641.3% | -391.1% | -3676.9% | — | — | — | — | — |
| EBIT | $-13.69M | $-19.19M | $-43.66M | $-83.47M | $-127.44M | $-159.24M | $-133.12M | — |
| Interest expense | $0.00 | $21000.00 | $811000.00 | $13000.00 | $4.36M | $1.56M | $1.73M | $1.60M |
| Income tax | — | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-13.73M | $-19.24M | $-45.74M | $-83.46M | $-123.48M | $-160.81M | $-134.85M | $-101.69M |
| Net income growth (YoY) | — | -40.1% | -137.7% | -82.5% | -47.9% | -30.2% | +16.1% | +24.6% |
| Profit margin | -664.3% | -401.2% | -3869.7% | — | — | — | — | — |